The FDA has approved other ICI drugs targeting T-cell-programmed cell death protein 1 (PD-1) (pembrolizumab, nivolumab, and cemiplimab), programmed cell death ligand 1 (PD-L1) (atezolizumab, avelumab, and durvalumab), and CTLA-4 (tremelimumab) (9) However, ICI may also activate T cells that target non-cancer tissues, thus resulting in immune-related adverse events (irAE) (10). This evidence concerns the gene CD274 and cancer.